If you have certain forms of breast cancer, your doctor might suggest Kadcyla (ado-trastuzumab emtansine) as a treatment option. It’s a prescription drug used to treat HER2-positive (HER2+) breast ...

The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The ...

All of the women in the study had progressed on two or more HER2-targeted therapies, including Herceptin (trastuzumab) and Tykerb (lapatinib). Kadcyla (ado-trastuzumab emtansine; T-DM1) reduced the ...

The Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual ...

Roche’s Kadcyla needs some oomph, and the Swiss drugmaker’s new data might just do the trick. The company is teeing up a new filing for its next-generation breast cancer drug, hoping to gin up more ...

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – – Long-term data also showed continued benefit in invasive ...

The FDA approval of Roche/Genentech's breast cancer drug T-DM1 (brand name Kadcyla) last week has caused a mixed reaction from healthcare analysts. The FDA approval of Roche/Genentech’s breast cancer ...

On the news, Kadcyla in this setting is now approved in 27 countries worldwide. The European Commission has approved Roche’s Kadcyla (trastuzumab emtansine) for the adjuvant (after surgery) treatment ...

As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla. The Swiss pharma firm has announced that it ...

ZURICH, Feb 5 () - Swiss drugmaker Roche aims to broaden the use of its Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of its older mainstay Herceptin. Roche ...

The Ontario Municipal Employees Retirement System (OMERS) has acquired the residual rights to receive royalty payments on sales of Kadcyla, a HER2-positive breast cancer therapy, for US$65 million.

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the ...